Pilot Study Initiated for BloodBased Breast Test

first_img May 1, 2018 — Overlake Medical Center in Bellevue, Wash., announced it has enrolled 85 patients in a pilot study of a blood test to assess breast cancer risk. The test may determine which women with abnormal or inconclusive screening mammography results are at low risk for invasive breast cancer. This technology, requiring a simple blood draw, will help physicians assess the likelihood of invasive cancer or precancerous lesions with difficult-to-interpret mammogram images, thus potentially reducing the need for invasive biopsies.The EarlyGuard Breast Test is being developed by Toray Molecular Oncology Laboratory (TMOL) in Brisbane, Calif. The multi-center prospective clinical trial is enrolling 400 patients at seven medical institutions nationwide. Overlake is the only hospital in Washington State participating, and is the second highest enrolling site nationwide.Despite its effectiveness in reducing breast cancer deaths, screening mammography is associated with a high false positive rate, or inconclusive results that lead to costly and invasive follow-up procedures, such as additional breast imaging tests or a tissue biopsy. “It’s satisfying to be a part of advancing science,” said Overlake’s Steve Scallon, M.D., the study’s principal investigator. “It may be a helpful way for clinicians to better differentiate between high- and low-risk patients in the future.”According to the American Cancer Society, for every woman screened, approximately 10 percent will be recalled for further testing, of which only three percent ultimately will be diagnosed with breast cancer. According to the Centers for Disease Control and Prevention, over 65 percent of women in the U.S. over the age of 40 are being screened every other year. For those patients who have been recommended to have an ultrasound guided biopsy, 75 percent of them will have a negative result. These false positives have the consequence of increased short-term anxiety for the women undergoing evaluation.For patients like Reshil Offutt of Woodinville, Wash., whose screening mammography placed her in the American College of Radiology’s Breast Imaging Reporting and Data System (BI-RADS) Category 4 meaning suspicious for malignancy, the waiting period before the biopsy and afterwards while waiting for results was stressful. “I scaled back on work after the biopsy and spent that week researching online and worrying,” said Offutt, whose biopsy showed her lump to be benign. “Anything that shortens the wait time is a good thing.”Results of the pilot study are expected in early summer 2018. A pilot study is a necessary first step in exploring a new clinical intervention. A larger efficacy trial is expected to start in winter 2018.For more information: www.toray.com Related Content FacebookTwitterLinkedInPrint分享 News | Brachytherapy Systems | August 14, 2019 Efficacy of Isoray’s Cesium Blu Showcased in Recent Studies August 14, 2019 — Isoray announced a trio of studies recently reported at scientific meetings and published in medica read more Images of regions of interest (colored lines) in the white matter skeleton representation. Data from left and right anterior thalamic radiation (ATR) were averaged. Image courtesy of C. Bouziane et al. News | Colonoscopy Systems | August 06, 2019 Rise in Early Onset Colorectal Cancer Not Aligned With Screening Trends A new study finds that trends in colonoscopy rates did not fully align with the increase in colorectal cancer (CRC) in… read more News | Radiation Therapy | August 15, 2019 First Patient Enrolled in World’s Largest Brain Cancer Clinical Trial Henry Ford Cancer Institute is first-in-the-world to enroll a glioblastoma patient in the GBM AGILE Trial (Adaptive… read more Image courtesy of Imago Systems News | Neuro Imaging | August 16, 2019 ADHD Medication May Affect Brain Development in Children A drug used to treat attention-deficit/hyperactivity disorder (ADHD) appears to affect development of the brain’s… read more center_img News | Oncology Diagnostics | May 01, 2018 Pilot Study Initiated for Blood-Based Breast Test Liquid biopsy increases clarity of inconclusive screening mammogram results, may reduce incidence of invasive biopsies News | Mammography | August 14, 2019 Imago Systems Announces Collaboration With Mayo Clinic for Breast Imaging Image visualization company Imago Systems announced it has signed a know-how license with Mayo Clinic. The multi-year… read more News | PACS | August 09, 2019 Lake Medical Imaging Selects Infinitt for Multi-site RIS/PACS Infinitt North America will be implementing Infinitt RIS (radiology information system)/PACS (picture archiving and… read more News | Cardiovascular Ultrasound | August 07, 2019 Contrast Use in First Transthoracic Echocardiogram for Heart Failure Reduces Repeat Testing Heart failure is the fourth most common cause for all admission to U.S. hospitals, and it is the most common reason for… read more News | CT Angiography (CTA) | August 06, 2019 Artificial Intelligence Improves Heart Attack Risk Assessment When used with a common heart scan, machine learning, a type of artificial intelligence (AI), does better than… read more News | Artificial Intelligence | August 13, 2019 Artificial Intelligence Could Yield More Accurate Breast Cancer Diagnoses University of California Los Angeles (UCLA) researchers have developed an artificial intelligence (AI) system that… read more News | Pediatric Imaging | August 14, 2019 Ultrasound Guidance Improves First-attempt Success in IV Access in Children August 14, 2019 – Children’s veins read more last_img

Leave a Reply

Your email address will not be published. Required fields are marked *